Circulating histocompatibility antigen (HLA) gene products may help differentiate benign from malignant indeterminate pulmonary lesions.

Autor: Kanangat S; Department of Biochemistry, United States., Seder CW; Department of Cardiovascular and Thoracic Surgery, United States., Pergande MR; Department of Pathology, United States., Lobato GC; Department of Biochemistry, United States., Fhied CL; Department of Pathology, United States; Department of Cell & Molecular Medicine, Rush University Medical Center, Chicago, IL 60612, United States., Raouf MF; Department of Cardiovascular and Thoracic Surgery, United States., Liptay MJ; Department of Cardiovascular and Thoracic Surgery, United States., Borgia JA; Department of Biochemistry, United States; Department of Pathology, United States; Department of Cell & Molecular Medicine, Rush University Medical Center, Chicago, IL 60612, United States. Electronic address: jeffrey_borgia@rush.edu.
Jazyk: angličtina
Zdroj: Human immunology [Hum Immunol] 2018 Jul; Vol. 79 (7), pp. 558-563. Date of Electronic Publication: 2018 Apr 12.
DOI: 10.1016/j.humimm.2018.04.003
Abstrakt: Background: This study explores the potential diagnostic utility of soluble Human Leukocyte Antigen (sHLA) molecules differentially released by lung adenocarcinoma and benign lung lesions.
Methods: Conditioned media from the NSCLC cell lines H358 and H1703 were immunoblotted for soluble isoforms of major histocompatibility complex (MHC) class I (ABC) and II (DRB1, DMB, and DQ) antigens. Sera from 25 patients with benign and 25 patients with malignant lesions were similarly evaluated to appraise the potential diagnostic value.
Results: Higher concentrations of soluble HLA class I molecules were observed in conditioned medium for the highly-invasive H1703 cell line, relative to the more indolent H358 cells. Evaluation of these markers against a cohort of 50 cases demonstrated that patients with malignant lesions possess higher levels of HLA class I and II molecules relative to those with benign lesions (p < 0.05), with exception to the primary isoform, DQA1, which was suppressed in malignancies. An analysis of biomarker performance via ROC analysis revealed promising performance (AUC > 0.75) for DMB and the 26 kDa isoform of DQ in distinguishing lesion pathology.
Conclusions: Soluble HLA molecules may have diagnostic value for early-stage NSCLC. Validation studies are currently underway using sera from a lung cancer screening cohort.
(Copyright © 2018. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: